See the DrugPatentWatch profile for Ubrelvy
Ubrelvy (ubrogepant) received FDA approval for the acute treatment of migraine with or without aura in adults on December 23, 2019 [1]. This marked the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for this indication [1][2].
How does Ubrelvy work for migraines?
Ubrelvy targets the CGRP pathway, which is believed to play a role in migraine pathophysiology [2]. By blocking the binding of CGRP to its receptor, Ubrelvy is thought to reduce neurogenic inflammation and vasodilation associated with migraines [2].
What is the difference between Ubrelvy and other migraine treatments?
Unlike triptans, which are also used for acute migraine treatment, Ubrelvy is not a vasoconstrictor and is approved for use in patients with a history of cardiovascular events [3]. It represents a novel mechanism of action compared to older acute migraine therapies [2].
When does Ubrelvy patent expire?
Information regarding specific patent expiry dates for Ubrelvy is available through resources like DrugPatentWatch.com [4]. Companies track these patents to understand market exclusivity and potential entry points for generic or biosimilar competition.
Who makes Ubrelvy?
Ubrelvy is manufactured by AbbVie [1].
What clinical data supports Ubrelvy's approval?
Ubrelvy's approval was based on two pivotal Phase 3 clinical trials, ACHOU-1 and ACHOU-2. These studies demonstrated that Ubrelvy was superior to placebo in achieving pain freedom and freedom from the most bothersome migraine-associated symptom at two hours post-dose [1].
What are the potential side effects of Ubrelvy?
The most common side effects reported in clinical trials included nausea and fatigue [1].
Can Ubrelvy be used for migraine prevention?
Ubrelvy is approved solely for the acute treatment of migraine and is not indicated for migraine prevention [1].
Are there other oral CGRP receptor antagonists for migraine?
Nurtec ODT (rimegepant) is another oral CGRP receptor antagonist approved for the acute treatment of migraine with or without aura in adults, and it is also indicated for migraine prevention [5].
What is the typical cost of Ubrelvy?
Pricing for Ubrelvy can vary based on insurance coverage, pharmacy, and dosage. Patients often seek information on cost savings programs or patient assistance programs offered by the manufacturer [6].
What are the regulatory milestones for Ubrelvy?
Following its initial FDA approval in December 2019 for acute migraine treatment, Ubrelvy later received approval for a second migraine indication. In June 2023, the FDA approved Ubrelvy for the preventive treatment of episodic migraine in adults who have had at least four migraine days per month during the previous four weeks [7].
What are the key considerations for patients using Ubrelvy?
Patients should discuss their migraine history, including any cardiovascular conditions, with their healthcare provider to determine if Ubrelvy is an appropriate treatment option [3]. Understanding the dosing regimen and potential side effects is also crucial [1].
What are the challenges and future outlook for oral CGRP antagonists?
The development of oral CGRP antagonists like Ubrelvy and Nurtec ODT has expanded treatment options for migraine sufferers. Future research and clinical experience will continue to refine their role in migraine management, including comparisons with other treatment classes and the long-term efficacy and safety profiles [2][5][7]. The patent landscape for these drugs will also influence market dynamics and the availability of generic alternatives.
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-ubrelvy-ubrogepant-migraine-treatment
[2] https://www.drugpatentwatch.com/blog/ubrelvy-ubrogepant-fda-approval-migraine-treatment
[3] https://www.drugpatentwatch.com/blog/ubrelvy-treatment-migraine-cardiovascular-risk
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/drug-approvals/fda-approves-nurtec-odt-rimegepant-migraine
[6] https://www.drugpatentwatch.com/blog/ubrelvy-cost-and-patient-assistance
[7] https://www.fda.gov/drugs/drug-approvals/fda-approves-ubrelvy-second-migraine-indication